



ELEVATION OF TROPONIN T AND N-TERMINAL PRO-B-TYPE NATRIURETIC PEPTIDE (NT- PRO BNP) IN HEART FAILURE PATIENTS WITH CKD

Biochemistry

Mohammed Siddique Ahmed Khan

Department of Biochemistry, Shadan Institute of Medical Sciences, Teaching Hospital, Research centre, R.R District, Telangana State, India.

Mohammad Ibrahim Shaik*

Department of Biochemistry, Shadan Institute of Medical Sciences, Teaching Hospital, Research centre, R.R District, Telangana State, India. *Corresponding Author

Shaik Mahmood

Department of Physiology, Deccan College of Medical Sciences, Owaisi Hospital & Research Centre, Hyderabad, Telangana State, India.

ABSTRACT

Elevation of Troponin T and N-Terminal pro-B-type natriuretic peptide (NT-proBNP) are commonly and strongly predictable biomarkers of Heart Failure (HF) patients with CKD. The present study included 150 people with CKD. We examined the association of baseline levels of elevation of TnT and NT-pro BNP with Heart Failure (HF) and CKD patients, after the adjustment for demographic factors, traditional cardiovascular risk factors and biomarkers of Chronic Kidney Disease. Constant medication application and mineral metabolism biomarkers cause Heart Failure and CKD. At base line, elevation of TnT levels ranged from < 5.0 to 1000 pg/ml and NT-proBNP levels ranged from < 5.0 to 35000 pg/ml. Compared to normal controls for TnT $< 5.8 - 25.8$ pg/ml and NT_proBNP $54 - 340$ pg/ml.

With this conclusion the elevation of TnT and NT-prBNP were strongly associated with incident of Heart Failure (HF) among with severe CKD. Elevations in these biomarkers may indicate subclinical changes in volume and myocardial stress that subsequently contribute to clinical Heart Failure (HF) with CKD.

KEYWORDS

Cardiovascular disease, Heart failure, Kidney disease, Troponin T and – Terminal pro-B-type natriuretic peptide (NT-proBNP).

INTRODUCTION

Raised Troponin T and N – Terminal Pro - B – type Natriuretic Peptide (NT – pro BNP) are more significant in cardiac problems and in chronic renal failure. However in heart attack, they rise and fall but in renal failure the rise is constant. Troponin T regulate heart muscles and tissue contraction. NT – pro BNP is vasoactive hormones that have major role in regulating blood pressure (BP) and volume through direct effects on the kidney and systemic vasculature and represent a favorable aspects of neurohumoral activation. Troponin is a group of three proteins Troponin C, T, and I Troponin I T are the cardiac markers, they regulate heart muscle and tissue contraction. These proteins are released after the damage of heart muscles. The greater the damage to the heart, the higher the Troponin levels in the blood. Troponin levels may be rise approximately 4 to 6 hours after heart damage. Troponin in blood remain raised upto two weeks. Three different natriuretic peptides have been characterized namely A type (atrial) natriuretic peptide, B type (brain) natriuretic peptide (BN) and C type natriuretic peptide. BNP is synthesized as amino acid precursor protein and undergoes intracellular modification to a pro hormone (Pro BNP) which comprises 108 amino acids and is secreted from left ventricle (LV) in response to increased myocardial wall stress. It is also found in the kidney glomerular filtration. It has major role in the elimination of BNP. In contrast NT – pro - - BNP is thought to be principally cleared by renal excretion.

Heart Failure (HF) is the most common cardiovascular complication among patients with Chronic Kidney Disease (CKD) and it imposes significant morbidity and mortality. Among people with CKD subclinical cardiac dysfunction (e.g early changes in left ventricular structure and function) The cardiac biomarkers high sensitivity Troponin T (hs TnT) and N – terminal pro – B – type natriuretic peptide (NT – pro BNP) have been shown to predict heart failure in the general population. The use of hs TnT and NT – pro BNP to aid in the diagnosis of heart failure among patients with CKD. It has been limited because of concerns that elevated levels may be caused by reduced renal excretion. The elevation in TnT and NT – pro BNP would be independently associated with incident Heart Failure (HF) among patients with mild to severe Chronic Kidney Disease (CKD)

MATERIAL AND METHODS

The present study included 150 patients with end-stage renal failure undergoing chronic hemodialysis, all patients were examined by electrocardiography and two – dimensional echocardiography, at the Departments of Cardiology, Nephrology, Biochemistry and

Physiology, Shadan Institute of Medical Sciences, Teaching Hospital & Research Centre, R.R District, Telangana State, India. Based on the examination results patients were found for concentric left ventricular hypertrophy, Acute Myocardial Infarction (AMI) and signs of Coronary Artery Disease (CAD) Heart Failure (HF). Blood was collected from patients before dialysis. Renal Function Test (RFT) was measured in Cobas clinical Analyser and serum electrolytes were measured in ST – 200 PLUS Electrolytes Analyzer Sensa Core. The serum TnT was measured on an ES 700 analyser (Roche Diagnostics) and NT – ProBNP was measured on Mini Vidas (Roche Diagnostics) We have examined the association of baseline levels of elevation of TnT and NT – pro BNP with Heart Failure (HF) and Chronic Kidney Disease (CKD) patients, after adjustment for their demographic factors, traditional cardiovascular risk factors clinical and biomarkers of Heart Failure (HF) and Chronic Kidney Disease (CKD). The patients for constant medication application and mineral metabolism biomarkers cause Heart Failure (HF) and Chronic Kidney Disease (CKD). At the base line elevation of TnT levels ranged from < 5.0 to 1000 pg/ml and NT – pro BNP levels ranged from < 5.0 to 35000 pg/ml. This is compared to normal controls for TnT < 5.0 to 25.8 pg/ml and NT – proBNP 54.5 to 340 pg/ml. With this conclusion elevation of TnT and NT- ProBNP were strongly associated with incident of Heart Failure (HF) among with the severe Chronic Kidney Disease (CKD). Elevation in these biomarkers may indicate subclinical changes in volume and myocardial stress that subsequent contributed to clinical Heart Failure (HF) and with Chronic Kidney Disease (CKD).

Demographic, Clinical and Physiobiochemical characteristics of Heart Failure (HF) and Chronic Kidney Disease (CKD) patients

Characteristics	Patients	Controls	P Value
Age (Years)	40 – 60	30 – 50	< 0.001
Sex (Male%)	50 – 60	40 – 60	
(Female%)	30 – 40	30 – 50	
Body Mass Index kg/m ²	35 – 40	30 – 35	
Blood Pressure mm/Hg			
Systolic	120 – 180	110 – 120	
Diastolic	100 – 120	70 – 80	

Renal Function Test (RFT)

Blood Urea (mg/dl)	80 – 185	15 – 40	< 0.001
Serum Creatinine (mg/dl)	4.5 – 12.5	0.8 – 1.5	
Serum Uric Acid (mg/dl)	8.5 – 10.5	3.5 – 7.0	
Serum Potassium (mEq/L)	5.0 – 8.0	3.5 – 5.0	
GRF (Ru/ml)	150 – 300	110 – 200	
24 Hours Urinary Proteins (g/day)	1.0 – 2.5	0.08 – 0.9	

P values <0.001 are subject to all the parameters

RESULTS

Among participants in our study for Heart Failure (HF) with Chronic Kidney Disease (CKD) The elevated average mean SD \pm values were found as mean age was 58.5, for both male and female, mean body mass index mean 32.5 kg/m², mean blood pressure systolic 150mm/Hg, diastolic 110 mm/Hg, renal function test mean blood urea 132.5 mg/dl, mean serum creatinine 8.50 mg/dl, mean serum uric acid 9.5 mg/dl. Mean serum potassium level was 6.5 mEq/L, Mean Glomerular Filtration Rate (GRF) was 225 Ru/ml and Mean 24 hours urinary protein was 1.75 g/day. Beside the above elevated values in Heart Failure (HF) and Chronic Kidney Disease (CKD) patients more significant for hTNT > 10000 pg/ml and NT- pro – BNP > 35000 pg/ml were found.

CONCLUSION

In conclusion among patients with Chronic Kidney Disease (CKD), elevated levels of hsTNT and NT- proBNP were strongly associated with incident with Heart Failure (HF), even after adjustment for a broad range of demographic, traditional, clinical and physiobiochemical may indicate early changes in volume and myocardial stress that subsequently contribute to clinical Heart Failure (HF).

REFERENCES

1. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy.[Am J Kidney Dis. 2005]
2. Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure.[Eur J Heart Fail. 2009]
3. Prevalence and determinants of troponin T elevation in the general population.[Circulation. 2006]
4. Impact of kidney function on plasma troponin concentrations after coronary artery bypass grafting.[Nephrol Dial Transplant. 2008]
5. Review Cardiac troponins in renal insufficiency: review and clinical implications.[J Am Coll Cardiol. 2002]
6. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate.[Eur Heart J. 2012]
7. Association of cardiac troponin T with left ventricular structure and function in CKD.[Am J Kidney Dis. 2013]
8. Interpreting cardiac troponin results from high-sensitivity assays in chronic kidney disease without acute coronary syndrome.[Clin Chem. 2012]
9. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population.[JAMA. 2010]
10. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient.[Circulation. 2004]
11. Review Differential diagnosis of elevated troponins [Heart. 2006]
12. Prognostic value of highly sensitive troponin T on cardiac events in patients with chronic kidney disease not on dialysis.[Heart Vessels. 2013]
13. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis.[JAMA. 2003]
14. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis.[Kidney Int. 2007]
15. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.[Eur J Heart Fail. 2012]
16. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.[JAMA. 2005]
17. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy.[Am J Kidney Dis. 2005]
18. Correlates of N-terminal prohormone brain natriuretic peptides in African Americans with hypertensive chronic kidney disease: the African American Study of Kidney Disease and Hypertension.[Am J Nephrol. 2009]
19. Natriuretic peptides in chronic kidney disease.[Clin J Am Soc Nephrol. 2008]
20. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality.[Clin Chem. 2007]
21. N-terminal prohormone brain natriuretic peptide as a predictor of cardiovascular disease and mortality in blacks with hypertensive kidney disease: the African American Study of Kidney Disease and Hypertension (AASK).[Circulation. 2008]
22. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF.[Am J Kidney Dis. 2004]
23. High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and

24. glomerular filtration rate.[Eur Heart J. 2012]
24. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay.[J Am Coll Cardiol. 2014]
25. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations.[Clin Chem. 2003]
26. Left ventricular hypertrophy in nondiabetic predialysis CKD.[Am J Kidney Dis. 2005]
27. Ventricular function and all-cause mortality in chronic kidney disease patients with angiographic coronary artery disease.[J Nephrol. 2010]
28. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.[JAMA. 2011]
29. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods.[J Am Soc Nephrol. 2003]
30. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.[Clin J Am Soc Nephrol. 2009]
31. The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods.[J Am Soc Nephrol. 2003]
32. Analytical validation of a high-sensitivity cardiac troponin T assay.[Clin Chem. 2010]
33. Survival after the onset of congestive heart failure in Framingham Heart Study subjects.[Circulation. 1993]
34. Variability of creatinine measurements in clinical laboratories: results from the CRIC study.[Am J Nephrol. 2010]
35. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.[Clin Chem. 2007]
36. Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study.[Am J Kidney Dis. 2012]
37. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.[J Am Soc Echocardiogr. 2005]
38. Associations between kidney function and subclinical cardiac abnormalities in CKD.[J Am Soc Nephrol. 2012]